Myriad Genetics (MYGN) Return on Invested Capital (2011 - 2026)

Myriad Genetics (MYGN) has 16 years of Return on Invested Capital data on file, last reported at 0.01% in Q1 2026.

• Return on Invested Capital for Q1 2026 came in at 0.01%, down 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (down 1.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Invested Capital eased to 0.01% in Q1 2026 per MYGN's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.0% in Q1 2022 and troughed at 0.01% in Q3 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2024 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Return on Invested Capital changed 0 bps in 2022, then decreased 1 bps in 2025.
• A 5-year view of Return on Invested Capital shows it stood at 0.0% in 2022, then tumbled by 169 bps to 0.0% in 2023, then surged by 50 bps to 0.0% in 2024, then sank by 335 bps to 0.01% in 2025, then fell by 12 bps to 0.01% in 2026.
• Business Quant data shows MYGN's Return on Invested Capital at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.